MedTrace Logo

Quetiapine Augmentation for Treatment-resistant PTSD

NCT00292370 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2019-10-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the response of veterans with PTSD without an optimal response to paroxetine to quetiapine augmentation versus placebo.

Conditions

  • Combat Disorders
  • Stress Disorders, Post-Traumatic

Interventions

DRUG

Open Label (OL) Paroxetine

Open-label Paroxetine

DRUG

Placebo

Double-blind placebo taken with OL paroxetine

DRUG

Quetiapine

Double-blind quetiapine taken with OL paroxetine

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Mark B Hamner, MD BS · Ralph H. Johnson VA Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-12-31
Completion
2009-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00292370 on ClinicalTrials.gov